Information Library
Demonstrating Value
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by:
- Most Recent
- Title
-
Podcast: Clinical / Commercial Convergence
August 26, 2010
John Doyle, Ph.D., MPH, Vice President and Practice Leader for Market Access with the Consulting group at Quintiles, explains the concept of clinical/commercial convergence. -
A Blueprint for Clinical/Commercial Convergence
August 5, 2010
The development model for bio pharmaceutical companies must shift from two divergent paths to one that combines these two resources with market access strategy, information and capabilities. -
THE NEW HEALTH REPORT FINDS GREATER INFLUENCE FOR PATIENTS ON DRUG DEVELOPMENT
June 15, 2010 - Patients are emerging as an increasingly strong group when it comes to influencing the success and failure of new drugs – according to a newly published New Health Report commissioned by Quintiles.
-
Patient-centric commercialisation
May 6, 2010
NGP Article March 2010 Issue by Justin van Gennep -
Podcast: Biopharma's Commercialization Challenges
April 19, 2010
Michael Ackermann, Ph.D., Vice President of Global Commercial Strategy and Alliance, Global Commercial Solutions at Quintiles, discusses the factors that are leading to a radical shift in how biopharmaceutical products are developed and commercialized. -
New Voices, New Opportunities: Toward a Patient-Centric Biopharmaceutical Commercialization Model
February 19, 2010
Biopharmaceutical companies must learn to navigate the increasingly tricky waters of commercializing products by adjusting to the needs of a new set of stakeholders. -
Rewarding Innovation and Value: What is the Role of Comparative Effectiveness Research
October 6, 2009
The impact of comparative effectiveness research on the future of drug development. -
Comparative Effectiveness Research as a Drug Development Tool
September 1, 2009
A Q&A with John Doyle, Vice President and Practice Leader of Quintiles Consulting, sheds light on the complex issue of comparative effectiveness research, and its strategic importance in successful and efficient biopharmaceutical development. -
A New Gold Standard
May 1, 2008
May 2008 - John Doyle, DrPH, practice leader for market access at Quintiles Consulting, discusses the concept of a health economic balance sheet and the need for evidence-based pricing for biopharmaceutical valuation.
Page 1 of 1 (9 results)
